close

Recommended Free CME and Other Educational Activities

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Join us for this live, interactive webinar focused on advancing personalized care for patients with extensive-stage small cell lung cancer (ES-SCLC). Led by nationally recognized SCLC experts, this session will explore real-world challenges in the community oncology setting, the latest evidence on new and emerging therapies, and…
Free Live Webinar1.0 CME/CEMOCAug 4, 2026
Access
Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Despite significant progress in biomarker testing for detection of actionable mutations, many patients with advanced and metastatic non-small cell lung cancer (NSCLC) still do not receive comprehensive guideline-concordant testing. …
Free Live Webinar1.0 CME/CEAug 13, 2026
Access
Changing Paradigms in Paroxysmal Nocturnal Hemoglobinuria: Understanding New Pathways, Clinical Evidence, and Practice Guidelines

Changing Paradigms in Paroxysmal Nocturnal Hemoglobinuria: Understanding New Pathways, Clinical Evidence, and Practice Guidelines

Join leading hematology experts for a dynamic live webinar exploring the rapidly evolving treatment landscape in paroxysmal nocturnal hemoglobinuria (PNH). …
Free Live Webinar1.0 CME/CEJul 29, 2026
Access
New and Emerging Therapies in IgA Nephropathy: Latest Data and Clinical Implications

New and Emerging Therapies in IgA Nephropathy: Latest Data and Clinical Implications

Advances in the understanding of IgA nephropathy (IgAN) pathophysiology have ushered in a wave of targeted therapies with the potential to transform personalized care. …
Free Live Webinar1.0 CME/CEMOCJul 21, 2026
Access
Advances in Perioperative Pain Management: Integrating Emerging Non-Opioid Therapies Into Multimodal Treatment Pathways

Advances in Perioperative Pain Management: Integrating Emerging Non-Opioid Therapies Into Multimodal Treatment Pathways

Acute pain is highly prevalent in the perioperative setting and can significantly impact recovery and long-term outcomes, underscoring the importance of skilled assessments and the use of multimodal analgesic (MMA) strategies. Emerging non-opioid therapies are expanding the available options for designing effective, opioid-reducing pain…
Free Live Webinar1.0 CME/CEAug 27, 2026
Access
Advancing TNBC Care: Clinical Insights and Effective Application of Emerging Treatment Strategies Across Lines of Therapy

Advancing TNBC Care: Clinical Insights and Effective Application of Emerging Treatment Strategies Across Lines of Therapy

Join leading experts for a focused webinar on the evolving treatment landscape of metastatic triple-negative breast cancer (mTNBC). Through a review of key clinical trial updates and real-world insights from a recent quality improvement initiative, faculty will discuss practical strategies for integrating emerging therapies, including…
Free Live Webinar1.0 CME/CEMOCAug 25, 2026
Access
Amplify, Apply, Advance: Bridging Academic Expertise and Community Practice to Elevate CML Care

Amplify, Apply, Advance: Bridging Academic Expertise and Community Practice to Elevate CML Care

The management of chronic myeloid leukemia (CML) continues to evolve, with expanding treatment options, growing emphasis on molecular monitoring, and increasing opportunities to achieve treatment-free remission (TFR). Yet, translating rapidly emerging evidence into individualized treatment decisions remains challenging, particularly…
Free Live Webinar1.0 CME/CESep 22, 2026
Access
Evolving Frontiers in Systemic Lupus Erythematosus: Bridging Pathophysiology and Practice

Evolving Frontiers in Systemic Lupus Erythematosus: Bridging Pathophysiology and Practice

The historically stagnant pharmacologic landscape for systemic lupus erythematosus (SLE) is currently poised for rapid expansion - offering clinicians unprecedented opportunity to employ personalized treatment approaches with targeted agents.Join us for this live TheraTalk webinar where two renowned rheumatologists will take a deep dive…
Free Live Webinar1.0 CME/CEAug 26, 2026
Access
Fostering Resilience to Lead and Delegate HIV Services Through Disruption and Change

Fostering Resilience to Lead and Delegate HIV Services Through Disruption and Change

Shifting priorities and resource constraints contribute to a climate of uncertainty, complicating the delivery of consistent, high-quality HIV care. As systemic pressures mount, HCPs are challenged with finding new ways to meet the needs of patients while navigating the logistical complexities of modern antiretroviral implementation.To…
Free Live Webinar0.5 CME/CEMOCJul 21, 2026
Access
Bridging the Divide in Adult Immunization: Strategies for Vaccine Equity and Confidence

Bridging the Divide in Adult Immunization: Strategies for Vaccine Equity and Confidence

A fragmented policy landscape and diverging vaccination guidelines leave clinicians to navigate a surge of misinformation and widening immunization disparities. To restore patient trust, healthcare providers must be equipped with the latest evidence and communication tools to dismantle these barriers and support equitable protection for…
Free Live Meeting1.0 CME/CEJul 27, 2026
Register
Precision Oncology in mHSPC: Translating Emerging Evidence Into Clinical Practice

Precision Oncology in mHSPC: Translating Emerging Evidence Into Clinical Practice

The therapeutic landscape of metastatic hormone-sensitive prostate cancer (mHSPC) is rapidly transforming with rapid advances in the development of novel biomarkers and targeted therapies. Tune in to this video podcast as two leading experts in prostate cancer review the latest clinical data on the emerging targeted therapies in mHSPC…
Free Podcast1.5 CME/CE
Access
Practical Implications of Targeted Therapies in mHSPC Care

Practical Implications of Targeted Therapies in mHSPC Care

Rapid advances in the development of novel biomarkers and targeted therapies for metastatic hormone-sensitive prostate cancer (mHSPC) have led to a shift towards more individualized, biomarker-driven treatment decision-making. …
Free Podcast2.25 CME/CE
Access
Recognizing Patients With High Risk T1D: Clinical Indicators of IAH and Recurrent Severe Hypoglycemia

Recognizing Patients With High Risk T1D: Clinical Indicators of IAH and Recurrent Severe Hypoglycemia

Impaired awareness of hypoglycemia (IAH) and recurrent severe hypoglycemia (SH) significantly increase mortality risk and quality of life burden for patients with type 1 diabetes (T1D).In this first of three video podcasts recorded during a live satellite symposium at ENDO 2026, a panel of experts explores how to identify at-risk…
Free Podcast0.5 CME/CE
Access
Current and Emerging Strategies for Addressing IAH and Recurrent Severe Hypoglycemia in T1D

Current and Emerging Strategies for Addressing IAH and Recurrent Severe Hypoglycemia in T1D

Recognizing patients with impaired awareness of hypoglycemia (IAH) and recurrent severe hypoglycemia is the first step. The next challenge is determining and applying the most effective strategies to address these conditions to improve patient outcomes and quality of life for patients with type 1 diabetes (T1D).In this second of three…
Free Podcast0.5 CME/CE
Access
Evaluating β-Cell Replacement for T1D: Individualizing Treatment Through Shared Decision-Making

Evaluating β-Cell Replacement for T1D: Individualizing Treatment Through Shared Decision-Making

Patients with type 1 diabetes (T1D) who experience recurrent severe hypoglycemia and impaired awareness of hypoglycemia (IAH) may be candidates for β-cell replacement, but treatment decisions require careful consideration of both the potential benefits of restoring endogenous insulin production and the risks related to chronic…
Free Podcast0.5 CME/CE
Access
Partnering for Progress in AML: Practical Strategies for Collaborative Care

Partnering for Progress in AML: Practical Strategies for Collaborative Care

Join leading experts for this highly practical webcast focused on strengthening community-academic co-management strategies in acute myeloid leukemia (AML). Designed for busy hematology/oncology care teams, this session highlights real-world insights from a quality improvement initiative and provides actionable guidance on integrating…
Free Online Activity0.5 CME/CE
Access
Mastering the HER2 Spectrum for Individualized Management of Advanced/Metastatic NSCLC

Mastering the HER2 Spectrum for Individualized Management of Advanced/Metastatic NSCLC

With HER2 established as an actionable driver of advanced/metastatic non-small cell lung cancer (NSCLC), integrating HER2 testing and HER2-targeted tyrosine kinase inhibitors (TKIs) into clinical practice is essential for healthcare providers navigating today's complex clinical landscape. …
Free Clinical Case Study0.5 CME/CE
Access
Unlocking Expertise in Bispecific ADCs: Therapeutic Rationale and Emerging Data in NSCLC, TNBC, and Urothelial Carcinoma

Unlocking Expertise in Bispecific ADCs: Therapeutic Rationale and Emerging Data in NSCLC, TNBC, and Urothelial Carcinoma

Bispecific antibody-drug conjugates (ADCs) are an emerging class of ADCs poised to expand treatment options for solid tumors. Bispecific ADCs are unique in their dual-targeting mechanisms that set them apart from single target therapies. Understanding their distinction is essential as they move toward clinical practice. …
Free Booster Quiz0.5 CME/CEMOC
Access
Navigating Diagnostic Complexity in Leptomeningeal Metastases: Real-World Case Challenges in Timely Diagnosis of Leptomeningeal Metastases

Navigating Diagnostic Complexity in Leptomeningeal Metastases: Real-World Case Challenges in Timely Diagnosis of Leptomeningeal Metastases

Leptomeningeal metastases (LM) is an aggressive, severe complication of advanced solid tumors often presenting with multifocal, nonspecific symptoms, making early diagnosis challenging for affected patients. …
Free Clinical Case Study0.5 CME/CE
Access
Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk

Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk

Tune in to this expert TheraTalk webcast designed to equip hematology/oncology care teams with the knowledge and confidence to integrate emerging menin inhibitor therapies into the management of relapsed/refractory (R/R) acute myeloid leukemia (AML). …
Free Online Activity0.5 CME/CEMOC
Access
Assess, Align, Act: A Practical Guide to ASCVD Risk Assessment and LDL-C Goal Setting

Assess, Align, Act: A Practical Guide to ASCVD Risk Assessment and LDL-C Goal Setting

Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality, yet gaps in consistent risk assessment and treatment optimization persist in primary care. Time constraints, workflow variability, and uncertainty around guideline implementation often limit the routine use of standardized risk assessment…
Free Online Activity0.5 CME/CE
Access